Physician profile
Suzanne L Lowry
NPI 1346252111
$1,941.43
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,908 · 2020: $33.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $1,582.98 | 2019 | |
| Pfizer INC. | $68.00 | 2019 | |
| Astellas Pharma US INC | $62.64 | 2019 | |
| Lupin INC. | $53.37 | 2019 | |
| Therapeuticsmd, INC. | $37.33 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $34.40 | 2019 | |
| Allergan, INC. | $33.56 | 2020 | |
| Shire North American Group INC | $28.83 | 2019 | |
| Exeltis, USA INC. | $27.65 | 2019 | |
| Avion Pharmaceuticals | $12.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.